171 related articles for article (PubMed ID: 35614293)
1. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
[TBL] [Abstract][Full Text] [Related]
2. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
[TBL] [Abstract][Full Text] [Related]
3. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
[TBL] [Abstract][Full Text] [Related]
4. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
5. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
[TBL] [Abstract][Full Text] [Related]
8. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
[TBL] [Abstract][Full Text] [Related]
9. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
10. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
[TBL] [Abstract][Full Text] [Related]
11. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
[TBL] [Abstract][Full Text] [Related]
12. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
13. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
[TBL] [Abstract][Full Text] [Related]
14. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
[TBL] [Abstract][Full Text] [Related]
15. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
[TBL] [Abstract][Full Text] [Related]
16. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
Mayo AL; Craven BC; McAdam LC; Biggar WD
Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
[TBL] [Abstract][Full Text] [Related]
17. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Houston C; Mathews K; Shibli-Rahhal A
Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Wilson N; Walker S; Hartigan C; Khan N; Page M; Robinson ME; Saleh DS; Smit K; Rauch F; Siminoski K; Ward LM
J Clin Endocrinol Metab; 2024 Jan; 109(2):536-548. PubMed ID: 37610420
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate.
Diacinti D; Pisani D; Cipriani C; Celli M; Zambrano A; Diacinti D; Kripa E; Iannacone A; Colangelo L; Nieddu L; Pepe J; Minisola S
Bone; 2021 Feb; 143():115608. PubMed ID: 32829035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
